Genomic Health, Inc.
GHDX
GHDX was delisted on the 7th of November, 2019.
120 hedge funds and large institutions have $807M invested in Genomic Health, Inc. in 2013 Q4 according to their latest regulatory filings, with 18 funds opening new positions, 34 increasing their positions, 44 reducing their positions, and 9 closing their positions.
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
8% more funds holding
Funds holding: 111 → 120 (+9)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
2% less capital invested
Capital invested by funds: $824M → $807M (-$17.2M)
23% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 44
67% less call options, than puts
Call options by funds: $447K | Put options by funds: $1.37M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Baillie Gifford & Co
Edinburgh,
United Kingdom
|
+$10.1M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$8.28M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$3.25M |
| 4 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
+$2.64M |
| 5 |
Morgan Stanley
New York
|
+$2.55M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
Apex Capital Management
Dayton,
Ohio
|
-$11.5M |
| 2 |
MAA
Managed Account Advisors
Jersey City,
New Jersey
|
-$3.19M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$1.84M |
| 4 |
QI
Quotient Investors
New York
|
-$1.83M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$1.27M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TCCM
126
Timber Creek Capital Management
Boston,
Massachusetts
| – | -$30K | -1,000 | Closed |
|
|
FHA
127
First Horizon Advisors
Memphis,
Tennessee
| – | -$12K | -385 | Closed |
|
128
Group One Trading
Chicago,
Illinois
| – | -$5.65K | -178 | Closed |
|
|
RFC
129
Russell Frank Company
Seattle,
Washington
| – | -$3K | -85 | Closed |
|
GHDX Hedge Fund Activity: Q4 2013 in Review
120 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Genomic Health, Inc. (GHDX) for Q4 2013, worth a combined $807M — down 2.1% from $824M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new GHDX positions and 9 closed out — a net gain of 9 holders — while 34 added to existing stakes and 44 trimmed.
The largest buyer was Baillie Gifford & Co, adding an estimated $10.1M. The largest seller was Apex Capital Management, cutting an estimated $11.5M.
- 120 institutional investors held Genomic Health, Inc. (GHDX) as of Q4 2013, up from 111 in Q3 2013.
- Funds reported $807M of Genomic Health, Inc. stock for Q4 2013, down 2.1% quarter-over-quarter.
- 18 funds opened new Genomic Health, Inc. positions in Q4 2013 and 9 closed out, a net change of +9 holders.
- The largest Genomic Health, Inc. buyer in Q4 2013 was Baillie Gifford & Co, an estimated $10.1M added.
- The largest Genomic Health, Inc. seller in Q4 2013 was Apex Capital Management, an estimated $11.5M sold.
Based on aggregated 13F filings for Q4 2013.